Orchard Therapeutics plc Long Term Debt

Orchard Therapeutics plc (ORTX) currently reports a long-term debt of $33M as of September 2023. That compares with $44M in the prior-year period — down 25.9% year over year. Use the charts on this page to explore Orchard Therapeutics plc's long-term debt history and peer comparisons.

Orchard Therapeutics plc's long-term debt decreased from $44M to $33M — a 25.9% year-over-year decrease (period ending September 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Orchard Therapeutics plc reported $33M in long-term debt as of September 2023. That compares with $44M in the prior-year period — down 25.9% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current long-term debt of $33M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Orchard Therapeutics plc, and consider following ORTX for alerts when major investors trade the stock.

Orchard Therapeutics plc is classified in the Healthcare sector. On long-term debt, it currently shows $33M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ORTX with unrelated industries.